Skip to contentT
TScan Therapeutics, Inc.
T
TCRXTScan Therapeutics, Inc. Q3 2024 · 10-Q
Revenue$1.05M$1.05M−73.0% vs Q3 2023 Net Income-$29.89M-$29.89MN/M vs Q3 2023 EPS Diluted-$0.25-$0.25N/M vs Q3 2023 Operating Income-$32,622,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
TScan Therapeutics, Inc. · CIK 1783328 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$29,288,000N/M Margins · derivedOperating margin-3109.8%−2473.1 pt vs Q3 2023
Net margin-2849.1%−2257.5 pt vs Q3 2023
ended Sep 30, 2024 · filed Nov 12, 2024 · 43 d after period end